Loading
A phase 3 trial of Ribociclib and Exemestane in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer is a phase 3 interventional study registered as NCT05827081 by Novartis Pharmaceuticals, with 1400 participants planned, started 2024-02-28 and due to reach its primary completion in 2029-09-07. Interventions recorded: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide and Exemestane.
Shares Advanced Accelerator Applications (Novartis), Ribociclib, CDK4/6 inhibitors, Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Ribociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.